Wednesday, October 04, 2006

Posted: MedImmune Inc. v. Genentech Inc. Supreme Court Oral Argument

Today, the Supreme court heard oral arguments on MedImmune Inc. v. Genentech Inc. At issue in the case is whether a company must stop paying royalties on a patent license in order to challenge the validity of the patent. MedImmune is paying licensing fees to Genentech on antibody technology used in MedImmune's childhood respiratory drug, Synagis. At the same time, Medimmune wants to challenge Genentech's patent in court.

The transcript for the oral arguments have been posted by the Supreme Court, and can be downloaded here.

Seja o primeiro a comentar

Powered By Blogger


This Blog/Web Site ("Blog") is for educational purposes only and is not legal advice. Use of the Blog does not create any attorney-client relationship between you and Peter Zura or his firm. Persons requiring legal advice should contact a licensed attorney in your state. Any comment posted on the Blog can be read by any Blog visitor; do not post confidential or sensitive information. Any links from another site to the Blog are beyond the control of Peter Zura and does not convey his, or his past or present employer(s) approval, support, endorsement or any relationship to any site or organization.

The 271 Patent Blog © 2008. Template by Dicas Blogger.